Shots:

• Appia Bio to receive $875M as an up front- equity investment- and milestone along with royalties. Kite will be responsible for the development- manufacturing- and commercialization of the product identified through the collaboration
• The collaboration will utilize Kite’s chimeric Ag receptors and Appia Bio’s allogeneic cell technology platform to develop off-the-shelf cell therapies
• Appia Bio will lead preclinical and early clinical research of two HSC-derived CAR-iNKT products with CARs provided by Kite

  | Ref: Businesswire | Image: Businesswire